BioCentury | Apr 15, 2013
Clinical News

Pharmadigm preclinical data

...to normal, whereas vehicle and saline-treated animals had no measurable blood flow in the area. Pharmadigm Inc....
BioCentury | Aug 30, 2004
Company News

Inflabloc inflammation, autoimmune news

...a $3 million series B financing round, the company changed its name to Inflabloc from Pharmadigm Inc....
BioCentury | Nov 24, 2003
Company News

StemCells management update

...Business: Gene/Cell therapy Hired: Barbara Araneo as VP of development, formerly SVP of R&D at Pharmadigm Inc....
BioCentury | Sep 3, 2002
Company News

Hollis-Eden, Pharmadigm deal

...HEPH gained exclusive global rights to certain undisclosed patents from Pharmadigm and the University of Utah...
...a focus on HIV/AIDS, malaria and hepatitis B. Hollis-Eden Pharmaceuticals Inc. (HEPH), San Diego, Calif. Pharmadigm Inc....
BioCentury | Aug 29, 2002
Company News

HEPH, Pharmadigm licensing deal

...Hollis- Eden Pharmaceuticals (HEPH) received exclusive global rights to certain patents from Pharmadigm (Salt Lake City...
BioCentury | Jan 14, 2002
Finance

Hat in Hand?

...$15.0M Spotfire $15.0M Inhibitex $15.0M Neuron $12.2M BioNumerik $12.0M Withdrew IPO on 11/01 Xanthon $12.0M Pharmadigm...
BioCentury | Dec 3, 2001
Company News

Altea Development Corp. board of directors update

...Corp., Atlanta, Ga. Business: Drug delivery Appointed: Ned Weinshenker, president, CEO, and a director of Pharmadigm Inc. WIR...
BioCentury | Aug 27, 2001
Finance

Money Hunters

...$13.4M Filed for IPO 8/13/01 Neuron $12.2M BioNumerik $12.0M Filed for IPO 3/2/01 Xanthon $12.0M Pharmadigm...
BioCentury | Aug 27, 2001
Finance

Money Hunters

...$13.4M Filed for IPO 8/13/01 Neuron $12.2M BioNumerik $12.0M Filed for IPO 3/2/01 Xanthon $12.0M Pharmadigm...
BioCentury | Jan 8, 2001
Company News

StemCells management update

...Calif. Business: Biomanufacturing Hired: Martin McGlynn as president and CEO, formerly president and CEO of Pharmadigm Inc....
Items per page:
1 - 10 of 21
BioCentury | Apr 15, 2013
Clinical News

Pharmadigm preclinical data

...to normal, whereas vehicle and saline-treated animals had no measurable blood flow in the area. Pharmadigm Inc....
BioCentury | Aug 30, 2004
Company News

Inflabloc inflammation, autoimmune news

...a $3 million series B financing round, the company changed its name to Inflabloc from Pharmadigm Inc....
BioCentury | Nov 24, 2003
Company News

StemCells management update

...Business: Gene/Cell therapy Hired: Barbara Araneo as VP of development, formerly SVP of R&D at Pharmadigm Inc....
BioCentury | Sep 3, 2002
Company News

Hollis-Eden, Pharmadigm deal

...HEPH gained exclusive global rights to certain undisclosed patents from Pharmadigm and the University of Utah...
...a focus on HIV/AIDS, malaria and hepatitis B. Hollis-Eden Pharmaceuticals Inc. (HEPH), San Diego, Calif. Pharmadigm Inc....
BioCentury | Aug 29, 2002
Company News

HEPH, Pharmadigm licensing deal

...Hollis- Eden Pharmaceuticals (HEPH) received exclusive global rights to certain patents from Pharmadigm (Salt Lake City...
BioCentury | Jan 14, 2002
Finance

Hat in Hand?

...$15.0M Spotfire $15.0M Inhibitex $15.0M Neuron $12.2M BioNumerik $12.0M Withdrew IPO on 11/01 Xanthon $12.0M Pharmadigm...
BioCentury | Dec 3, 2001
Company News

Altea Development Corp. board of directors update

...Corp., Atlanta, Ga. Business: Drug delivery Appointed: Ned Weinshenker, president, CEO, and a director of Pharmadigm Inc. WIR...
BioCentury | Aug 27, 2001
Finance

Money Hunters

...$13.4M Filed for IPO 8/13/01 Neuron $12.2M BioNumerik $12.0M Filed for IPO 3/2/01 Xanthon $12.0M Pharmadigm...
BioCentury | Aug 27, 2001
Finance

Money Hunters

...$13.4M Filed for IPO 8/13/01 Neuron $12.2M BioNumerik $12.0M Filed for IPO 3/2/01 Xanthon $12.0M Pharmadigm...
BioCentury | Jan 8, 2001
Company News

StemCells management update

...Calif. Business: Biomanufacturing Hired: Martin McGlynn as president and CEO, formerly president and CEO of Pharmadigm Inc....
Items per page:
1 - 10 of 21